Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 5,492 shares at $301.07 ($1.7M) on 2023-03-16, disclosed to the SEC on 2023-03-20.
Scheduled sale ($1.7M) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $300.54 | 2,482 | $746K | 45.2% |
| 2 | $300.54 | 2,482 | $746K | 45.2% |
| 3 | $301.07 | 264 | $79K | 4.8% |
| 4 | $301.07 | 264 | $79K | 4.8% |
| Total | $300.59 avg | 5,492 | $1.7M | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-02-16 | $1.3M | — | Filing → |